Castle Bioscience News Today

Erik Jones and the Erik Jones Foundation (EJF) will kick off Skin Cancer and Melanoma Awareness Month this weekend at Kansas Speedway and continue to educate fans throughout the month of May

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Mar 12, 2024--

Full-Year Revenue Surges by 60% with Significant Advances in Dermatological and Gastroenterological Diagnostics

Renowned eye cancer expert and study investigator, Amy Schefler, M.D., will share early data from a study to explore the potential for developing a complementary test that would be tailored for...

Cancer Genetics (NASDAQ:CGIX – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both small-cap health care and social assistance companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk. Insider & Institutional […]

Castle Biosciences (NASDAQ:CSTL – Get Free Report) and Cancer Genetics (NASDAQ:CGIX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends. Institutional & Insider Ownership 85.8% of Castle […]

MedTech Acquisition (NASDAQ:MTAC – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Profitability This table compares MedTech Acquisition and […]

Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) – Leerink Partnrs boosted their Q3 2023 earnings estimates for shares of Castle Biosciences in a research report issued on Wednesday, August 2nd. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.87) for the quarter, up from their previous forecast […]

Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript August 2, 2023 Castle Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.06 EPS, expectations were $1.01. Operator: Good afternoon, and welcome to Castle Biosciences Second Quarter 2023 Conference Call. As a reminder, today’s call is being recorded. We will begin today’s call with opening […]